Human Genome Sciences Reports Progress With Late-Stage Products and New I...(imminent in a Phase 1 clinical trial ofH...),Health

Date:5/28/2008

imminent in a Phase 1 clinical trial of HGS1029 in patients with advanced solid tumors. Preclinical studies of HGS1029 in combination with the Company's TRAIL receptor antibodies demonstrated synergistic activity against a number of cancer types. HGS1029 has also shown significant anti-tumor activity alone and in combination with other agents in a broad range of cancers. HGS plans to develop its TRAIL receptor antibodies and IAP inhibitors in combination with one another and in combination with other therapeutic agents.

HGS reacquired the rights to its TRAIL receptor antibodies from GSK in April 2008 in return for a reduction in royalties due to HGS if Syncria(R) (albiglutide) is commercialized. The fees and milestone payments due to HGS under the original Syncria agreement, some of which have already been received, could amount to as much as $183 million and remain unchanged in the amended agreement.

HGS views the oncology portfolio as a key driver of future growth beyond the launch of the Company's late-stage products. Reacquiring the rights to HGS-ETR1 and HGS-ETR2 (lexatumumab) gives HGS the opportunity to drive and advance this important program more aggressively by enabling the exploration of new alliances with a more optimal structure that could bring development expertise and resources, commercial leadership, near-term milestone payments and cost-sharing. HGS is also capable financially and organizationally of taking the TRAIL receptor antibodies forward on its own, thus retaining 100% of the value.

Key milestones of advancement for the HGS oncology portfolio:

-- Potential new alliance(s) for TRAIL receptor antibodies.

-- Initiation of HGS1029 Phase 1 trial in solid tumors imminent.

-- Initiation of HGS-ETR1 randomized trial in hepatocellular cancer.

-- Data expected from HGS-ETR1 Phase 2 trial in multiple myeloma in the

third quarter of 2008.

-- Data expected from HGS-ETR1 Phase 2 trial in n
'/>"/>

SOURCE Human Genome Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
2. St. Jude Finds Dancing Hair Cells Are Key to Humans Acute Hearing
3. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
4. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
5. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
6. First Human Implant of New Archus Orthopedics Facet Replacement System
7. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Data Show SuperGens MP-470 is Safe in Humans
10. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
11. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent